Results 31 to 40 of about 1,483,959 (183)
Thrombosis in Myeloproliferative Neoplasms With JAK2V617F Mutation [PDF]
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders and are characterized by advanced proliferation and survival advantage. These abnormalities are considered to derive from the point mutation in exon 14 of the Janus kinase 2 genes (JAK2 V617F).
Tiantian, Sun, Lei, Zhang
openaire +2 more sources
Concomitant occurrence of BCR-ABL and JAK2V617F mutation [PDF]
To the editor: In a recent issue of the journal, Makishima et al[1][1] reported on the occurrence of mutations typically associated with Philadelphia-chromosome (Ph1) negative myeloproliferative (MPN)/ myelodysplastic neoplasms in 54 patients with typical chronic myelogenous leukemia (CML ...
PIERI, LISA +8 more
openaire +5 more sources
JAK2/STAT5 Pathway Mutation Frequencies in South African BCR/ABL Negative MPN Patients
Background: Mutations in JAK2/STAT5 proliferation pathway genes are key in the diagnosis of myeloproliferative neoplasms (MPNBCR/ABLneg), with JAK2V617F being found in 50-97% of MPNBCR/ABLneg subtypes.
Karen L. Shires +4 more
doaj +1 more source
CONTEXT.— Concomitant BCR-ABL1 and JAK2V617F in myeloproliferative neoplasms (MPNs) is rare, and its pathogenesis and clinical significance are unclear.
Yue Zhao +6 more
semanticscholar +1 more source
INTRODUCTION: The JAK2V617F mutation is present in the majority of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF). The impact of this mutation on disease phenotype in ET and PMF is still a matter of discussion.
İpek Yonal +6 more
doaj +1 more source
Association of High-Altitude Polycythemia with JAK2V617F Mutation in Pakistani Population. [PDF]
To assessthe prevalence of the JAK2V617F mutation in polycythemia patients living at high altitude. This was a cross-sectional study, conducted at the National Institute of Blood Diseasesand Bone Marrow Transplantation (NIBD-BMT), KarachifromJuly 2022 to July 2023.
Fayyaz F +6 more
europepmc +4 more sources
Clinical significance of the JAK2V617F mutation in patients with a myeloproliferative neoplasm has been the target of intensive research in recent years. However, there is considerably uncertainty about prognosis in JAK2V617F positive individuals without
Camilla Nielsen +4 more
doaj +1 more source
Background: JAK2V617F mutation is the most prevalent molecular abnormality in myeloproliferative neoplasms (MPNs) and has become a valuable marker for diagnosis of MPNs. Almost all patients with polycythemia vera (PV) have this acquired mutation. However,
Haythem A. AL-Rubaie +2 more
doaj +1 more source
Visual screening for JAK2V617F mutation by a disposable dipstick
During the last 5 years, it was discovered that the JAK2V617F somatic mutation is present in virtually all patients with polycythemia vera and a large proportion of patients with essential thrombocythemia, primary myelofibrosis, and refractory anemia with ring sideroblasts and thrombocytosis.
Konstantou, J.K. +6 more
openaire +3 more sources
Exposure-Response Analyses of Ropeginterferon Alfa-2b in Essential Thrombocythemia. [PDF]
Abstract Ropeginterferon alfa‐2b is a new‐generation interferon therapy for the treatment of myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). This investigation was designed to characterize its population pharmacokinetics–pharmacodynamics (PopPK‐PD) and delineate exposure–response (E‐R) relationships in ET. A population PK
Qin A +20 more
europepmc +2 more sources

